Form 8-K - Current report:
SEC Accession No. 0001193125-24-100069
Filing Date
2024-04-18
Accepted
2024-04-18 08:40:56
Documents
16
Period of Report
2024-04-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d803577d8k.htm   iXBRL 8-K 37892
2 EX-10.1 d803577dex101.htm EX-10.1 144275
3 EX-10.2 d803577dex102.htm EX-10.2 115220
4 EX-99.1 d803577dex991.htm EX-99.1 13164
  Complete submission text file 0001193125-24-100069.txt   524749

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA krro-20240417.xsd EX-101.SCH 2892
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE krro-20240417_lab.xml EX-101.LAB 19500
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE krro-20240417_pre.xml EX-101.PRE 12184
20 EXTRACTED XBRL INSTANCE DOCUMENT d803577d8k_htm.xml XML 3942
Mailing Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139
Business Address ONE KENDALL SQUARE. BUILDING 600-700 SUITE 6-401 CAMBRIDGE MA 02139 617-468-1900
Korro Bio, Inc. (Filer) CIK: 0001703647 (see all company filings)

EIN.: 472324450 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39062 | Film No.: 24852960
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)